ONO-4817 | MMP Inhibitor V | CAS# 223472-31-9 | Inhibitor

MedKoo Cat#: 574797 | Name: ONO-4817

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ONO-4817 is an orally active non-peptidyl hydroxamate compound that acts as an effective broad-spectrum inhibitor against MMP-2, -3, -8, -9, -12, -13.

Chemical Structure

ONO-4817

CAS#223472-31-9

Theoretical Analysis

MedKoo Cat#: 574797

Name: ONO-4817

CAS#: 223472-31-9

Chemical Formula: C22H28N2O6

Exact Mass: 416.1947

Molecular Weight: 416.47

Elemental Analysis: C, 63.45; H, 6.78; N, 6.73; O, 23.05

Price and Availability

Size	Price	Availability	Quantity
2mg	USD 350.00	2 Weeks
5mg	USD 675.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

MMP Inhibitor V; ONO-4817; ONO 4817; ONO4817

IUPAC/Chemical Name

(2S,4S)-N-Hydroxy-5-ethoxymethyloxy-2-methyl-4-(4-phenoxybenzoyl)aminopentanamide

InChi Key

HDWWQELUBWGQGA-WMZOPIPTSA-N

InChi Code

InChI=1S/C22H28N2O6/c1-3-28-15-29-14-18(13-16(2)21(25)24-27)23-22(26)17-9-11-20(12-10-17)30-19-7-5-4-6-8-19/h4-12,16,18,27H,3,13-15H2,1-2H3,(H,23,26)(H,24,25)/t16-,18-/m0/s1

SMILES Code

O=C(NO)[C@@H](C)C[C@H](NC(C1=CC=C(OC2=CC=CC=C2)C=C1)=O)COCOCC

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

ONO-4817 is a potent inhibitor of matrix metalloproteinase (MMP).

In vitro activity:

To confirm the involvement of MMPs in TNF-α-induced upregulation of sCD146, this study treated HRMECs with TNF-α (50 ng/ml) or with TNF-α (50 ng/ml) plus the MMP inhibitor ONO-4817 (10 µM). Co-treatment of HRMECs with TNF-α plus ONO-4817 significantly attenuated TNF-α-induced upregulation of sCD146, indicating that TNF-α-promoted CD146 shedding is dependent on MMPs (Fig. 7C). Reference: Invest Ophthalmol Vis Sci. 2021 Jul 1;62(9):32. https://pubmed.ncbi.nlm.nih.gov/34293080/

In vivo activity:

A selective matrix metalloproteinase inhibitor, [2S,4S]-N-Hydroxy-5-ethoxymethyloxy-2-methyl-4-[4-phenoxybenzoyl] aminopentanamide (ONO-4817), significantly suppressed matrix metalloproteinase-9 activity 1 day after myocardial infarction. ONO-4817 also significantly prevented the development of cardiac dysfunction and left-ventricular dilatation in hamsters. Reference: Eur J Pharmacol. 2007 Oct 15;572(1):57-60. https://pubmed.ncbi.nlm.nih.gov/17643409/

Preparing Stock Solutions

The following data is based on the product molecular weight 416.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Abu El-Asrar AM, Nawaz MI, Ahmad A, Siddiquei MM, Allegaert E, Gikandi PW, De Hertogh G, Opdenakker G. CD146/Soluble CD146 Pathway Is a Novel Biomarker of Angiogenesis and Inflammation in Proliferative Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2021 Jul 1;62(9):32. doi: 10.1167/iovs.62.9.32. PMID: 34293080; PMCID: PMC8300056. 2. Muraishi Y, Mitani N, Fuse H, Saiki I. Effect of a matrix metalloproteinase inhibitor (ONO-4817) on lung metastasis of murine renal cell carcinoma. Anticancer Res. 2001 Nov-Dec;21(6A):3845-52. PMID: 11911256. 3. Takai S, Jin D, Inagaki S, Yamamoto D, Tanaka K, Miyazaki M. Significance of matrix metalloproteinase-9 in cardiac dysfunction during the very acute phase after myocardial infarction in hamsters. Eur J Pharmacol. 2007 Oct 15;572(1):57-60. doi: 10.1016/j.ejphar.2007.07.001. Epub 2007 Jul 10. PMID: 17643409. 4. Ro Y, Hamada C, Inaba M, Io H, Kaneko K, Tomino Y. Inhibitory effects of matrix metalloproteinase inhibitor ONO-4817 on morphological alterations in chlorhexidine gluconate-induced peritoneal sclerosis rats. Nephrol Dial Transplant. 2007 Oct;22(10):2838-48. doi: 10.1093/ndt/gfm323. Epub 2007 Jun 2. PMID: 17545675.

In vitro protocol:

In vivo protocol:

1. Takai S, Jin D, Inagaki S, Yamamoto D, Tanaka K, Miyazaki M. Significance of matrix metalloproteinase-9 in cardiac dysfunction during the very acute phase after myocardial infarction in hamsters. Eur J Pharmacol. 2007 Oct 15;572(1):57-60. doi: 10.1016/j.ejphar.2007.07.001. Epub 2007 Jul 10. PMID: 17643409. 2. Ro Y, Hamada C, Inaba M, Io H, Kaneko K, Tomino Y. Inhibitory effects of matrix metalloproteinase inhibitor ONO-4817 on morphological alterations in chlorhexidine gluconate-induced peritoneal sclerosis rats. Nephrol Dial Transplant. 2007 Oct;22(10):2838-48. doi: 10.1093/ndt/gfm323. Epub 2007 Jun 2. PMID: 17545675.